cagrilintide news New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Presenters to provide first look

The door shelves undergo the most temperature variation from repeated opening

The data showing cagrilintide preferentially reduces fat mass while preserving lean mass is compelling for researchers who care about body composition, not just the scale number

The cold environment inhibits hydrolysis, oxidation, and deamidation reactions that would otherwise destroy peptide bonds and biological activity

[DOI] [PMC free article] [PubMed] [Google Scholar] Zhang Y, Zhu W, Wang M, Xi P, Wang H, Tian D

However, community sources and pharmaceutical handling references consistently cite refrigeration at 2-8C as the documented best practice for punctured vials, for three reasons: Reduced microbial growth rate